Lincoln Pharmaceuticals Share Price
Sector: Biotechnology & Drugs
567.45 +6.45 (1.15%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
562.70
Today’s High
568.65
52 Week Low
500.00
52 Week High
975.00
563.00 -0.10 (-0.02%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
562.00
Today’s High
570.00
52 Week Low
499.00
52 Week High
979.50
Key Metrics
- Market Cap (In Cr) 1134.57
- Beta 0.64
- Div. Yield (%) 0.32
- P/B 1.68
- TTM P/E 13.41
- Sector P/E 22.43
- D/E 0
- Open Price 563.4
- Prev Close 561
Lincoln Pharmaceuticals Analysis
Price Analysis
-
1 Week0.6%
-
3 Months2.38%
-
6 Month-26.84%
-
YTD-28.33%
-
1 Year-7.53%
Risk Meter
- 46% Low risk
- 46% Moderate risk
- 46% Balanced Risk
- 46% High risk
- 46% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 0.00
- 0.00
- 0.00
- 0.00
- Buy
- 1
- 1
- 1
- 1
- Hold
- 0.00
- 0.00
- 0.00
- 0.00
- Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Strong Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Total
- 1
- 1
- 1
- 1
Lincoln Pharmaceuticals News
Debt-free small-cap stock hits 20% upper circuit, lifetime high; should you buy?
2 min read . 04 Dec 2024Lincoln Pharmaceuticals Q3 FY24 Results Live: Profit Rises by 29.74% YoY
1 min read . 10 Feb 2024Lincoln Pharmaceuticals Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 623.23
- Selling/ General/ Admin Expenses Total
- 112.45
- Depreciation/ Amortization
- 12.9
- Other Operating Expenses Total
- 117.96
- Total Operating Expense
- 534.64
- Operating Income
- 88.59
- Net Income Before Taxes
- 109.19
- Net Income
- 82.35
- Diluted Normalized EPS
- 41.11
- Period
- 2025
- Total Assets
- 797.01
- Total Liabilities
- 125.34
- Total Equity
- 671.67
- Tangible Book Valueper Share Common Eq
- 335.12
- Period
- 2025
- Cashfrom Operating Activities
- 93.02
- Cashfrom Investing Activities
- -78.95
- Cashfrom Financing Activities
- -6.4
- Net Changein Cash
- 7.67
- Period
- 2024
- Total Revenue
- 580.55
- Selling/ General/ Admin Expenses Total
- 188.96
- Depreciation/ Amortization
- 10.62
- Other Operating Expenses Total
- 0.17
- Total Operating Expense
- 491.24
- Operating Income
- 89.31
- Net Income Before Taxes
- 122.24
- Net Income
- 93.3
- Diluted Normalized EPS
- 46.59
- Period
- 2024
- Total Assets
- 700.29
- Total Liabilities
- 107.45
- Total Equity
- 592.84
- Tangible Book Valueper Share Common Eq
- 295.82
- Period
- 2024
- Cashfrom Operating Activities
- 63.22
- Cashfrom Investing Activities
- -57.34
- Cashfrom Financing Activities
- -5.18
- Net Changein Cash
- 0.7
- Period
- 2023
- Total Revenue
- 510.31
- Selling/ General/ Admin Expenses Total
- 167.24
- Depreciation/ Amortization
- 9.17
- Other Operating Expenses Total
- 0.02
- Total Operating Expense
- 429.76
- Operating Income
- 80.55
- Net Income Before Taxes
- 100.48
- Net Income
- 72.9
- Diluted Normalized EPS
- 36.49
- Period
- 2023
- Total Assets
- 587.42
- Total Liabilities
- 84.95
- Total Equity
- 502.47
- Tangible Book Valueper Share Common Eq
- 250.72
- Period
- 2023
- Cashfrom Operating Activities
- 39.26
- Cashfrom Investing Activities
- -36.64
- Cashfrom Financing Activities
- -4.5
- Net Changein Cash
- -1.88
- Period
- 2022
- Total Revenue
- 472.12
- Selling/ General/ Admin Expenses Total
- 148.19
- Depreciation/ Amortization
- 8.09
- Other Operating Expenses Total
- 0.03
- Total Operating Expense
- 384.43
- Operating Income
- 87.7
- Net Income Before Taxes
- 95.94
- Net Income
- 69.36
- Diluted Normalized EPS
- 34.67
- Period
- 2022
- Total Assets
- 534.36
- Total Liabilities
- 101.48
- Total Equity
- 432.88
- Tangible Book Valueper Share Common Eq
- 215.93
- Period
- 2022
- Cashfrom Operating Activities
- 76.13
- Cashfrom Investing Activities
- -78.08
- Cashfrom Financing Activities
- -2.56
- Net Changein Cash
- -4.5
- Period
- 2021
- Total Revenue
- 424.19
- Selling/ General/ Admin Expenses Total
- 130.15
- Depreciation/ Amortization
- 7.56
- Other Operating Expenses Total
- 0.18
- Total Operating Expense
- 344.38
- Operating Income
- 79.8
- Net Income Before Taxes
- 83.72
- Net Income
- 62.22
- Diluted Normalized EPS
- 31.18
- Period
- 2021
- Total Assets
- 459.37
- Total Liabilities
- 84.08
- Total Equity
- 375.29
- Tangible Book Valueper Share Common Eq
- 182.83
- Period
- 2021
- Cashfrom Operating Activities
- 69.27
- Cashfrom Investing Activities
- -64.23
- Cashfrom Financing Activities
- -5.75
- Net Changein Cash
- -0.7
- Period
- 2020
- Total Revenue
- 386.49
- Selling/ General/ Admin Expenses Total
- 128.39
- Depreciation/ Amortization
- 7.33
- Other Operating Expenses Total
- 0.04
- Total Operating Expense
- 327.7
- Operating Income
- 58.79
- Net Income Before Taxes
- 67.23
- Net Income
- 51.44
- Diluted Normalized EPS
- 25.77
- Period
- 2020
- Total Assets
- 389.39
- Total Liabilities
- 76.3
- Total Equity
- 313.09
- Tangible Book Valueper Share Common Eq
- 151.75
- Period
- 2020
- Cashfrom Operating Activities
- 75.42
- Cashfrom Investing Activities
- -30.88
- Cashfrom Financing Activities
- -37.76
- Net Changein Cash
- 6.77
- Period
- 2019
- Total Revenue
- 366.18
- Selling/ General/ Admin Expenses Total
- 114.13
- Depreciation/ Amortization
- 6.68
- Other Operating Expenses Total
- 0.88
- Total Operating Expense
- 305.38
- Operating Income
- 60.8
- Net Income Before Taxes
- 62.19
- Net Income
- 48.71
- Diluted Normalized EPS
- 24.46
- Period
- 2019
- Total Assets
- 365.98
- Total Liabilities
- 96.64
- Total Equity
- 269.34
- Tangible Book Valueper Share Common Eq
- 129.85
- Period
- 2019
- Cashfrom Operating Activities
- 52.84
- Cashfrom Investing Activities
- -18.19
- Cashfrom Financing Activities
- -35.77
- Net Changein Cash
- -1.11
- Period
- 2025-03-31
- Total Revenue
- 168.18
- Selling/ General/ Admin Expenses Total
- 27.62
- Depreciation/ Amortization
- 3.23
- Other Operating Expenses Total
- 33.69
- Total Operating Expense
- 144.69
- Operating Income
- 23.49
- Net Income Before Taxes
- 16.25
- Net Income
- 11.58
- Diluted Normalized EPS
- 5.78
- Period
- 2025-03-31
- Total Assets
- 797.01
- Total Liabilities
- 125.34
- Total Equity
- 671.67
- Tangible Book Valueper Share Common Eq
- 335.12
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 93.02
- Cashfrom Investing Activities
- -78.95
- Cashfrom Financing Activities
- -6.4
- Net Changein Cash
- 7.67
- Period
- 2024-12-31
- Total Revenue
- 146.55
- Selling/ General/ Admin Expenses Total
- 27.98
- Depreciation/ Amortization
- 3.22
- Other Operating Expenses Total
- 26.27
- Total Operating Expense
- 126.11
- Operating Income
- 20.44
- Net Income Before Taxes
- 28.68
- Net Income
- 20.77
- Diluted Normalized EPS
- 10.37
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 161.21
- Selling/ General/ Admin Expenses Total
- 27.84
- Depreciation/ Amortization
- 3.22
- Other Operating Expenses Total
- 32.71
- Total Operating Expense
- 136.06
- Operating Income
- 25.15
- Net Income Before Taxes
- 34.78
- Net Income
- 26.33
- Diluted Normalized EPS
- 13.15
- Period
- 2024-09-30
- Total Assets
- 779.79
- Total Liabilities
- 140.53
- Total Equity
- 639.26
- Tangible Book Valueper Share Common Eq
- 319
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 42.32
- Cashfrom Investing Activities
- -37.1
- Cashfrom Financing Activities
- -0.83
- Net Changein Cash
- 4.39
- Period
- 2024-06-30
- Total Revenue
- 147.28
- Selling/ General/ Admin Expenses Total
- 29.02
- Depreciation/ Amortization
- 3.22
- Other Operating Expenses Total
- 25.29
- Total Operating Expense
- 127.77
- Operating Income
- 19.51
- Net Income Before Taxes
- 29.48
- Net Income
- 23.67
- Diluted Normalized EPS
- 11.82
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 142.49
- Selling/ General/ Admin Expenses Total
- 25.05
- Depreciation/ Amortization
- 2.69
- Other Operating Expenses Total
- 25.48
- Total Operating Expense
- 126.8
- Operating Income
- 15.7
- Net Income Before Taxes
- 22.22
- Net Income
- 18.6
- Diluted Normalized EPS
- 9.28
- Period
- 2024-03-31
- Total Assets
- 700.29
- Total Liabilities
- 107.45
- Total Equity
- 592.84
- Tangible Book Valueper Share Common Eq
- 295.82
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 63.22
- Cashfrom Investing Activities
- -57.34
- Cashfrom Financing Activities
- -5.18
- Net Changein Cash
- 0.7
- Period
- 2023-12-31
- Total Revenue
- 146.45
- Selling/ General/ Admin Expenses Total
- 26.44
- Depreciation/ Amortization
- 2.81
- Other Operating Expenses Total
- 23.26
- Total Operating Expense
- 119.6
- Operating Income
- 26.85
- Net Income Before Taxes
- 37.71
- Net Income
- 28.04
- Diluted Normalized EPS
- 14
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Lincoln Pharmaceuticals Technical
Moving Average
SMA
- 5 Day561.2
- 10 Day567.38
- 20 Day567.33
- 50 Day572.08
- 100 Day579.75
- 300 Day659.41
Lincoln Pharmaceuticals Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Bliss Gvs Pharma
- 157.05
- 8.25
- 5.54
- 184.95
- 101
- 1652.62
- Hester Biosciences
- 1868
- 51.25
- 2.82
- 3375.45
- 1246.75
- 1589.69
- Lincoln Pharmaceuticals
- 567.45
- 6.45
- 1.15
- 975
- 500
- 1134.57
- Kwality Pharmaceuticals
- 1014.55
- -10.35
- -1.01
- 1140
- 481
- 1054.68
- Anuh Pharma
- 212.1
- 4.05
- 1.95
- 249.95
- 148.05
- 1062.88
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Bliss Gvs Pharma
- 18.72
- 1.49
- 7.19
- 9.45
- Hester Biosciences
- 53.74
- 4.93
- 11.14
- 11.44
- Lincoln Pharmaceuticals
- 13.7
- 1.68
- 15.87
- 14.56
- Kwality Pharmaceuticals
- 26.72
- 4.03
- 26.54
- 13.21
- Anuh Pharma
- 21.88
- 3.18
- 17.15
- 7.35
Lincoln Pharmaceuticals Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 22-May-25
- Audited Results & Final Dividend
- 13-Feb-25
- Quarterly Results
- 14-Nov-24
- Quarterly Results
- 08-Aug-24
- Quarterly Results
- 16-May-24
- Audited Results & Final Dividend
- 08-Feb-24
- Quarterly Results
- 02-Nov-23
- Quarterly Results
- 10-Aug-23
- Quarterly Results
- 25-May-23
- Audited Results & Dividend
- 09-Feb-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 30-Sept-24
- 02-Sept-24
- AGM
- 30-Sept-23
- 28-Aug-23
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 22-May-25
- -
- -
- 1.8
- 16-May-24
- -
- 13-Sept-24
- 1.8
- 25-May-23
- -
- 15-Sept-23
- 1.5
- 19-May-22
- -
- 15-Sept-22
- 1.5
- 25-May-21
- -
- 16-Sept-21
- 1.5


